Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions

BMC Cancer

Katalin Dobra¹  László Székely²  Anders Hjerpe¹  Henriette Skribek²  Eviane Yousef-Fadhel¹  Aytekin Celep¹  Carl-Olof Hillerdal¹  Rita Ötvös²  Adam Szulkin¹ 

[1]Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital F-46, SE-141 86 Stockholm, Sweden

[2]Karolinska Institutet, Department of Microbiology Tumor and Cell Biology (MTC), Nobels väg 16, KI Solna Campus Karolinska Institutet, Box 280, SE-171 77 Stockholm, Sweden

关键词: ERCC1 and Individualized treatment;    RRM1;    Cytotoxic drugs;    Ex vivo chemosensitivity;    Chemotherapy;    Primary cells;    Pleural effusions;    Malignant mesothelioma;   

Others  :  1121031
DOI  :  10.1186/1471-2407-14-709

 received in 2014-04-16, accepted in 2014-08-27,  发布年份 2014

【 摘 要 】

Background

Patients with malignant mesothelioma have a poor prognosis and only 40% respond to first line treatment; a combination of pemetrexed and cisplatin or carboplatin. We used primary malignant mesothelioma cells and an ex vivo chemosensitivity assay with future purpose to predict best choice of treatment. The clinical outcome of these patients might be predicted by measuring drug sensitivity.

Methods

Pleural effusions containing primary malignant mesothelioma cells were received from the diagnostic routine. We characterized and tested the chemosensitivity of 18 malignant samples and four benign samples from 16 different patients with pleural effusions. Cells were seeded in a 384-well plate for a robotized ex vivo testing of drug sensitivity to 32 different drugs. The primary cells were further characterized by immunocytochemistry to evaluate the proportion of malignant cells and to study the RRM1 and ERCC1 reactivity, two proteins associated with drug resistance.

Results

We observed great individual variability in the drug sensitivity. Primary cell isolates were affected by between one and ten drugs, and resistant to the remaining tested drugs. Actinomycin D and daunorubicin were the two drugs effective in most cases. Adjusting efficiency of individual drugs for varying proportion of tumor cells and to the average effect on benign cells correlated with effect of pemetrexed, cisplatin and survival time. General drug sensitivity, proportion of malignant cells and reactivity to RRM1 correlated to each other and to survival time of the patients.

Conclusions

The proportion of malignant cells and RRM1 reactivity in the pleural effusions correlate to drug sensitivity and survival time. The variability in response to the commonly used chemotherapies emphasizes the need for tests that indicate best individual choice of cytotoxic drugs. The efficiency of the obtained results should preferably be corrected for admixture of benign cells and effects of given drugs on benign cells.

【 授权许可】

   
2014 Szulkin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Wagner JC, Sleggs CA, Marchand P: Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960, 17:260-271.
• [2]Suzuki Y: Pathology of human malignant mesothelioma–preliminary analysis of 1,517 mesothelioma cases. Ind Health 2001, 39(2):183-185.
• [3]Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J: Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965-1985. J Clin Oncol 1988, 6(1):147-153.
• [4]Porcel JM, Light RW: Diagnostic approach to pleural effusion in adults. Am Fam Physician 2006, 73(7):1211-1220.
• [5]Abakay A, Abakay O, Tanrikulu AC, Sezgi C, Sen H, Kaya H, Kucukoner M, Kaplan MA, Celik Y, Senyigit A: Effects of treatment regimens on survival in patients with malignant pleural mesothelioma. Eur Rev Med Pharmacol Sci 2013, 17(1):19-24.
• [6]Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Paoleti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644.
• [7]Nowak AK: Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. Ann Cardiothorac Surg 2012, 1(4):508-515.
• [8]Blayney JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Fennell DA: Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. Eur J Cancer 2012, 48(16):2983-2992.
• [9]Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33(1):9-23.
• [10]Wang J, Lohman GJ, Stubbe J: Enhanced subunit interactions with gemcitabine-5′-diphosphate inhibit ribonucleotide reductases. Proc Natl Acad Sci U S A 2007, 104(36):14324-14329.
• [11]Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Soria JC: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991.
• [12]Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Bepler G: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27(34):5808-5815.
• [13]Zimling ZG, Sorensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E: Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol 2012, 7(1):249-256.
• [14]Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, Schmid KW, Christoph DC: ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin Lung Cancer 2013, 14(5):558-567. e553
• [15]Zimling ZG, Sorensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E: A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2012, 70(5):743-754.
• [16]Szulkin A, Nilsonne G, Mundt F, Wasik AM, Souri P, Hjerpe A, Dobra K: Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy. PLoS One 2013, 8(6):e65903.
• [17]Besse B, Olaussen KA, Soria JC: ERCC1 and RRM1: ready for prime time? J Clin Oncol 2013, 31(8):1050-1060.
• [18]Mundt F, Nilsonne G, Arslan S, Csuros K, Hillerdal G, Yildirim H, Metintas M, Dobra K, Hjerpe A: Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS One 2013, 8(8):e72030.
• [19]Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW: Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. Dis Markers 2013, 35(2):119-127.
• [20]Creaney J, Dick IM, Segal A, Musk AW, Robinson BW: Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer 2013, 82(3):491-498.
• [21]Thylen A, Hjerpe A, Martensson G: Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001, 92(5):1224-1230.
• [22]Toole BP: Hyaluronan promotes the malignant phenotype. Glycobiology 2002, 12(3):37R-42R.
• [23]Liu Z, Dobra K, Hauzenberger D, Klominek J: Expression of hyaluronan synthases and hyaluronan in malignant mesothelioma cells. Anticancer Res 2004, 24(2B):599-603.
• [24]Asplund T, Heldin P: Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res 1994, 54(16):4516-4523.
• [25]Hassan R, Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008, 44(1):46-53.
• [26]Chang K, Pastan I, Willingham MC: Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992, 50(3):373-381.
• [27]Hassan R, Bera T, Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004, 10(12 Pt 1):3937-3942.
• [28]Hjerpe A: Liquid-chromatographic determination of hyaluronic acid in pleural and ascitic fluids. Clin Chem 1986, 32(6):952-956.
• [29]Dejmek A, Hjerpe A: The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol 2005, 32(3):160-166.
• [30]Flores-Staino C, Darai-Ramqvist E, Dobra K, Hjerpe A: Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer 2010, 68(1):39-43.
• [31]Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, Nowak AK, Robinson BW, Creaney J: A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology 2013, 45(1):44-48.
• [32]Klominek J, Robert KH, Hjerpe A, Wickstrom B, Gahrton G: Serum-dependent growth patterns of two, newly established human mesothelioma cell lines. Cancer Res 1989, 49(21):6118-6122.
• [33]Schmitter D, Lauber B, Fagg B, Stahel RA: Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 1992, 51(2):296-301.
• [34]Pelin-Enlund K, Husgafvel-Pursiainen K, Tammilehto L, Klockars M, Jantunen K, Gerwin BI, Harris CC, Tuomi T, Vanhala E, Mattson K, Linnainmaa K: Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients. Carcinogenesis 1990, 11(4):673-681.
• [35]Otvos R, Skribek H, Kis LL, Gloghini A, Markasz L, Flaberg E, Eksborg S, Konya J, Gergely L, Carbone A, Szekely L: Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines. BMC Cancer 2011, 11:441. BioMed Central Full Text
• [36]Skribek H, Otvos R, Flaberg E, Nagy N, Markasz L, Eksborg S, Masszi T, Kozma A, Adam E, Miseta A, Szekely L: Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. Exp Hematol 2010, 38(12):1219-1230.
• [37]Flaberg E, Sabelstrom P, Strandh C, Szekely L: Extended Field Laser Confocal Microscopy (EFLCM): combining automated Gigapixel image capture with in silico virtual microscopy. BMC Med Imaging 2008, 8:13. BioMed Central Full Text
• [38]Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J: Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008, 5(3):136-147.
• [39]Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS: The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006, 1(6):591-601.
• [40]Kindler HL: Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 2008, 9(2–3):171-179.
• [41]Nilsonne G, Olm E, Szulkin A, Mundt F, Stein A, Kocic B, Rundlof AK, Fernandes AP, Bjornstedt M, Dobra K: Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure. J Exp Clin Cancer Res 2009, 28:92. BioMed Central Full Text
• [42]Vilmar AC, Santoni-Rugiu E, Sorensen JB: Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. Ann Oncol 2013, 24(2):309-314.
• [43]Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Santoro A: Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006, 24(9):1443-1448.
• [44]Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G, Syrigos KN: Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer 2010, 11(1):30-35.
• [45]Hillerdal G, Sorensen JB, Sundstrom S, Riska H, Vikstrom A, Hjerpe A: Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 2008, 3(11):1325-1331.